文献速递肝病消化道肿瘤与早癌

直接抗病毒药物在BCLC-B/C期肝细胞癌姑息治疗中的应用

Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
PubMed 文献 · J Hepatol · 2021-02-11

本文综述直接抗病毒药物(DAA)在BCLC-B/C期肝细胞癌(HCC)患者中的使用数据。HCC患者被排除在DAA随机对照试验之外,DAA获益不明确;活动性HCC是DAA失败预测因素,DAA失败后肝硬化并发症改善减少或缺失;DAA对HCC复发影响存争议。建议个体化决策并知情告知风险获益。

要点

  • 活动性HCC是DAA治疗失败的预测因素
  • DAA失败后肝硬化并发症改善减少或缺失
  • DAA对HCC复发的影响仍存争议

核心结论

  • BCLC-B/C期HCC患者使用DAA的获益不明确,需个体化决策并知情告知所有潜在风险与获益。
  • 若肝功能改善与症状性HCC进展重叠,DAA的获益可能被最小化、恶化或完全抵消。
  • 若BCLC分期仅由肝功能障碍定义,优先DAA治疗的决策应基于肝移植选项和/或HCC分期。

研究设计与样本

  • 本文为综述,汇总BCLC-B/C期HCC患者使用DAA的当前数据。
  • HCC患者被系统排除在评估DAA有效性的随机对照试验之外。

主要发现

  • 活动性HCC是DAA治疗失败的预测因素。
  • 无HCC患者的研究显示,DAA失败后肝硬化并发症改善减少或缺失。
  • 即使DAA实现病毒清除,肝功能损害逆转可能慢于终末期癌症状态的发展。
  • DAA对HCC复发的影响仍是争议话题。

关键数值与推荐

  • DAA失败后肝硬化并发症改善减少或缺失(基于无HCC患者研究)。
  • 活动性HCC是DAA失败的预测因素。

临床怎么用

  • BCLC-B/C期HCC患者使用DAA应基于个体化评估决策。
  • 应向每位患者告知DAA使用的所有潜在风险与获益。
  • 建议采用共享决策方法,告知患者拟议医疗干预的所有潜在风险与获益。
  • 若肝功能改善与症状性HCC进展重叠,需评估DAA获益可能被抵消的风险。
  • 若BCLC分期仅由肝功能障碍定义,优先DAA治疗应基于肝移植选项和/或HCC分期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver Cancer (BCLC)-B/C stage hepatocellular carcinoma (HCC) is understudied. Patients with HCC have been systematically excluded from randomised controlled trials evaluating the effectiveness of DAAs. Thus, the benefits of DAAs in patients with HCC are less well defined. The presence of active HCC before the initiation of DAA treatment is reported to be a predictor of DAA failure, and studies in patients without HCC have demonstrated that improvements in cirrhosis complications were lower or absent after DAA failure. Even if viral eradication is achieved using DAAs, reversal of liver function impairment may take longer than the development of end-stage cancer status. Additionally, the impact of DAAs on HCC recurrence is still a controversial topic. Thus, the decision of whether to use DAAs should be made on a patient-by-patient basis, and each patient should be informed of all the potential risks and benefits associated with their usage. This document summarises the current data on the usage of DAAs in BCLC-B/C patients, discusses the concept of "the point of no return" in the setting of DAAs, and proposes tools for deciding the best option for each patient profile. If liver function improvement overlaps with symptomatic HCC progression, the benefits of DAAs could be minimised, worsened, or fully counterbalanced. If the BCLC stage is defined using only liver dysfunction, the decision to prioritise DAA treatment should be based on the option (or lack thereof) of liver transplantation and/or the HCC stage. We propose applying a shared decision-making approach, informing each patient of all the potential risks and benefits of the proposed medical intervention.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol. 2021. PMID: 33582128. doi:10.1016/j.jhep.2021.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。